Kyra J Fuchs, Marian van de Meent, Maria W Honders, Indu Khatri, Michel G D Kester, Eva A S Koster, Georgia Koutsoumpli, Arnoud H de Ru, Cornelis A M Van Bergen, Peter A van Veelen, Peter A C 't Hoen, Peter van Balen, Erik B van den Akker, Hendrik Veelken, Constantijn Jm Jm Halkes, J H Frederik Falkenburg, Marieke Griffioen
Allogeneic stem cell transplantation (alloSCT) is a curative treatment for hematological malignancies. After HLA-matched alloSCT, anti-tumor immunity is caused by donor T cells recognizing polymorphic peptides, designated minor histocompatibility antigens (MiHAs), that are presented by HLA on malignant patient cells. However, T cells often target MiHAs on healthy non-hematopoietic tissues of patients, thereby inducing side effects known as Graft-versus-Host Disease. Here, we aimed to identify the dominant repertoire of HLA-I-restricted MiHAs to enable strategies to predict, monitor or modulate immune responses after alloSCT...
March 1, 2024: Blood